8egi: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
 
Line 5: Line 5:
<table><tr><td colspan='2'>[[8egi]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8EGI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8EGI FirstGlance]. <br>
<table><tr><td colspan='2'>[[8egi]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8EGI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8EGI FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3&#8491;</td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CMO:CARBON+MONOXIDE'>CMO</scene>, <scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=VZN:{6-[(3-hydroxy-2-methylphenoxy)methyl]pyridin-2-yl}methyl+nitrate'>VZN</scene></td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CMO:CARBON+MONOXIDE'>CMO</scene>, <scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=VZN:[6-[(2-methyl-3-oxidanyl-phenoxy)methyl]pyridin-2-yl]methyl+nitrate'>VZN</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8egi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8egi OCA], [https://pdbe.org/8egi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8egi RCSB], [https://www.ebi.ac.uk/pdbsum/8egi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8egi ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8egi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8egi OCA], [https://pdbe.org/8egi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8egi RCSB], [https://www.ebi.ac.uk/pdbsum/8egi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8egi ProSAT]</span></td></tr>
</table>
</table>
Line 12: Line 12:
== Function ==
== Function ==
[https://www.uniprot.org/uniprot/HBA_HUMAN HBA_HUMAN] Involved in oxygen transport from the lung to the various peripheral tissues.
[https://www.uniprot.org/uniprot/HBA_HUMAN HBA_HUMAN] Involved in oxygen transport from the lung to the various peripheral tissues.
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Sickle cell disease (SCD) is caused by a single-point mutation, and the ensuing deoxygenation-induced polymerization of sickle hemoglobin (HbS), and reduction in bioavailability of vascular nitric oxide (NO), contribute to the pathogenesis of the disease. In a proof-of-concept study, we successfully incorporated nitrate ester groups onto two previously studied potent antisickling aromatic aldehydes, TD7 and VZHE039, to form TD7-NO and VZHE039-NO hybrids, respectively. These compounds are stable in buffer but demonstrated the expected release of NO in whole blood in vitro and in mice. The more promising VZHE039-NO retained the functional and antisickling activities of the parent VZHE039 molecule. Moreover, VZHE039-NO, unlike VZHE039, significantly attenuated RBC adhesion to laminin, suggesting this compound has potential in vivo RBC anti-adhesion properties relevant to vaso-occlusive events. Crystallographic studies show that, as with VZHE039, VZHE039-NO also binds to liganded Hb to make similar protein interactions. The knowledge gained during these investigations provides a unique opportunity to generate a superior candidate drug in SCD with enhanced benefits.
Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.,Huang B, Ghatge MS, Donkor AK, Musayev FN, Deshpande TM, Al-Awadh M, Alhashimi RT, Zhu H, Omar AM, Telen MJ, Zhang Y, McMahon TJ, Abdulmalik O, Safo MK Molecules. 2022 Oct 12;27(20). pii: molecules27206835. doi:, 10.3390/molecules27206835. PMID:36296435<ref>PMID:36296435</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 8egi" style="background-color:#fffaf0;"></div>


==See Also==
==See Also==

Latest revision as of 15:07, 13 August 2026

X-ray structure of carbonmonoxy hemoglobin in complex with VZHE039-NO

8egi, resolution 2.30Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA